Disruptive technology and hemophilia care: The multiple impacts of emicizumab
Abstract Emicizumab, a bispecific antibody mimicking the action of factor VIII (FVIII), is currently the first and only approved and increasingly accessible disruptive treatment option for hemophilia A, a disease so far mainly treated with frequent intravenous infusions of FVIII concentrates or bypa...
Na minha lista:
| Principais autores: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elsevier
2021-05-01
|
| Serier: | Research and Practice in Thrombosis and Haemostasis |
| Fag: | |
| Online adgang: | https://doi.org/10.1002/rth2.12508 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|